Date: 2014-09-18
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Cubist Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: * On September 18, 2014, Cubist Pharmaceutical announced the official opening of its international headquarters in Zurich, Switzerland, reinforcing its commitment to global public health. Located in a growing biopharmaceutical hub in Switzerland, the Company’s international operations complement the Cubist’s corporate headquarters in Lexington, Massachusetts in the United States.
To address the urgent need for new antibiotics, during 2014 Cubist expects to invest approximately $400M on antibiotic R&D, and is focusing its late-stage pipeline on addressing serious and potentially life-threatening healthcare-acquired bacterial infections. Led by Patrick Vink, M.D., Senior Vice President and General Manager of International Business at Cubist, the Company’s international operations will focus on preparing for the launch of potential new antibiotics in Europe during 2015. “We selected Zurich for the location of our international headquarters due to its proximity to other markets, access to top talent, and stable business climate, as well as its position as a thriving and growing biopharmaceutical hub” said Dr. Vink.
Cubist’s international has increased its global employee base to approximately 960, up 35% from 2012, when the company introduced the Building Blocks of Growth, its five-year strategic goals. Approximately 3 out of every 4 employees at Cubist are focused on the research, development, commercialization, and support of antibiotics. Cubist anticipates a significant employee presence internationally, and expects to have around 200 internationally-based employees, of which approximately 50 will be based in Zurich.
Financial terms:
Latest news:
